References
- 1. Ramakrishnan AV, Varghese TP, Vanapalli S, Nair NK, Mingate MD. Platelet activating factor: A potential biomarker in acute coronary syndrome? Cardiovascular Therapeutics. 2017;35:64-70.
- 2. Ma CY, Xu ZY, Wang SP, Peng HY, Liu F, Liu JH, Ren FX. Change of Inflammatory Factors in Patients with Acute Coronary Syndrome. Chin Med J (Engl). 2018;131:1444-1449.10.4103/0366-6999.233953600681129893361
- 3. Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, et al. Inflammation Following Acute Myocardial Infarction: Multiple Players, Dynamic Roles, and Novel Therapeutic Opportunities. Pharmacology & Therapeutics. 2018;186:73-87.10.1016/j.pharmthera.2018.01.001598100729330085
- 4. Fang L, Moore XL, Dart AM, Wang LM. Systemic inflammatory response following acute myocardial infarction. Journal of Geriatric Cardiology. 2015;12:305-312.
- 5. Nian M, Lee P, Khaper N, Liu P. Inflammatory Cytokines and Postmyocardial Infarction Remodeling. Circulation Research. 2004;94:1543-1553.10.1161/01.RES.0000130526.20854.fa15217919
- 6. Milano SS, Victorino de Mourna O, Bordin AAS, Marques GL. C-Reactive Protein Is a Predictor of Mortality in ST-Segment Elevation Acute Myocardial Infarction. International Journal of Cardiovascular Sciences. 2019;32:118-124.
- 7. Benedek T. Imaging Vulnerable Plaque in a Modern School of Cardiology – the PlaqueImage Project. Journal of Interdisciplinary Medicine. 2021;6:1-2.10.2478/jim-2021-0011
- 8. Stefanadis C, Antoniou CK, Tsiachris D, Pietri P. Coronary Atherosclerotic Vulnerable Plaque: Current Perspectives. J Am Heart Assoc. 2017;17:e005543.10.1161/JAHA.117.005543552404428314799
- 9. Li JJ, Fang CH. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses. 2004;63:100-102.10.1016/j.mehy.2004.01.02915193358
- 10. Seidman M, Mitchell R, Stone J. Cellular and Molecular Pathobiology of Cardiovascular Disease. Cambridge, MA: Academic Press, 2014; p. 221-237.10.1016/B978-0-12-405206-2.00012-0
- 11. Kumar V, Abbas KA, Aster J. Robbins Basic Pathology. 10th ed. Philadelphia, PA: Elsevier - Health Sciences Division, 2017; p. 335-343.
- 12. Groh L, Keating ST, Joosten LAB, et al. Monocyte and macrophage immunometabolism in atherosclerosis. Semin Immunopathol. 2018;40:203-214.10.1007/s00281-017-0656-7580953428971272
- 13. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664-1672.10.1161/01.CIR.0000087480.94275.9714530185
- 14. Hafiane A. Vulnerable Plaque, Characteristics, Detection, and Potential Therapies. J Cardiovasc Dev Dis. 2019,6(3):26.10.3390/jcdd6030026678760931357630
- 15. Gerculy R, Mitra N, Szabó E, Opincariu D, Chițu M, Benedek I. Management of Culprit and Non-Culprit Lesions in Acute Coronary Syndrome. Journal of Interdisciplinary Medicine. 2021;6:32-36.10.2478/jim-2021-0009
- 16. Gonçalves I, Ruijter H den, Nahrendorf M, Pasterkamp G. Detecting the vulnerable plaque in patients. Journal of Internal Medicine. 2015;278:520-530.10.1111/joim.1241426306911
- 17. Benedek T. The Link between Periodontal Disease, Inflammation and Atherosclerosis — an Interdisciplinary Approach. Journal of Interdisciplinary Medicine. 2017;2(S1):11-16.10.1515/jim-2017-0016